Tumor necrosis factor-alpha (TNF-alpha) converting enzyme contributes to production of TNF-alpha in synovial tissues from patients with rheumatoid arthritis. 2001

S Ohta, and M Harigai, and M Tanaka, and Y Kawaguchi, and T Sugiura, and K Takagi, and C Fukasawa, and M Hara, and N Kamatani
Institute of Rheumatology, Tokyo Women's Medical University, Japan.

OBJECTIVE Expression and function of tumor necrosis factor-alpha (TNF-alpha) converting enzyme (TACE) in synovia of patients with rheumatoid arthritis (RA) were examined to investigate posttranslational regulation of TNF-alpha production by TACE in RA. METHODS Expression of TACE protein was evaluated by immunohistochemistry. Cytokines and soluble cytokine receptors were measured by ELISA. TACE mRNA was detected by RT-PCR. The enzymatic activity of TACE was measured using TACE-specific fluorogenic substrate. RESULTS Expression of TACE at protein level in synovial tissue (ST) of patients with RA was significantly stronger than that of patients with osteoarthritis (OA). In RA, TACE was mainly expressed in CD68+ macrophage-like synovial cells. ST from 9 of 9 RA and 3 of 8 OA patients expressed TACE mRNA. RA ST cells possessed significantly higher TACE-like enzymatic activity than OA ST. A synthetic TACE inhibitor significantly reduced the release of TNF-alpha and p75 TNF receptor from RA ST cells. CONCLUSIONS TACE is an important regulator of the secretion of TNF-alpha from synovia of patients with RA.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008666 Metalloendopeptidases ENDOPEPTIDASES which use a metal such as ZINC in the catalytic mechanism. Metallo-Endoproteinases,Metalloendopeptidase
D005629 Frozen Sections Thinly cut sections of frozen tissue specimens prepared with a cryostat or freezing microtome. Frozen Section,Section, Frozen,Sections, Frozen
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000072198 ADAM17 Protein A disintegrin and metalloproteinase domain-containing protein that cleaves the membrane-bound precursor of TUMOR NECROSIS FACTOR-ALPHA to its mature form. It cleaves several other CELL SURFACE PROTEINS, including INTERLEUKIN-1 RECEPTOR TYPE II; TRANSFORMING GROWTH FACTOR ALPHA; L-SELECTIN; MUCIN-1; and AMYLOID BETA-PROTEIN PRECURSOR. It can also function as an activator of the Notch signaling pathway by mediating the cleavage of NOTCH RECEPTORS. ADAM-17,ADAM-17 Protein,CD156b Antigen,Disintegrin and Metalloproteinase Domain-Containing Protein 17,TACA (Enzyme),TACE (Enzyme),TNF-alpha Convertase,TNF-alpha Converting Enzyme,Tumor Necrosis Factor Alpha Convertase,Tumor Necrosis Factor-alpha Convertase,Tumor Necrosis Factor-alpha Converting Enzyme,ADAM 17 Protein,Antigen, CD156b,Convertase, TNF-alpha,Disintegrin and Metalloproteinase Domain Containing Protein 17,TNF alpha Convertase,TNF alpha Converting Enzyme,Tumor Necrosis Factor alpha Converting Enzyme
D001172 Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated. Rheumatoid Arthritis
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated
D013583 Synovial Membrane The inner membrane of a joint capsule surrounding a freely movable joint. It is loosely attached to the external fibrous capsule and secretes SYNOVIAL FLUID. Synovium,Membrana Synovialis Capsulae Articularis,Membrane, Synovial,Membranes, Synovial,Synovial Membranes
D013585 Synovitis Inflammation of the SYNOVIAL MEMBRANE. Plica Syndrome,Synovial Plica Syndrome,Synovial Hypertrophy,Synovial Thickening,Hypertrophies, Synovial,Hypertrophy, Synovial,Plica Syndrome, Synovial,Synovial Hypertrophies,Synovial Thickenings,Synovitides,Thickening, Synovial,Thickenings, Synovial
D014409 Tumor Necrosis Factor-alpha Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS. Cachectin,TNF-alpha,Tumor Necrosis Factor Ligand Superfamily Member 2,Cachectin-Tumor Necrosis Factor,TNF Superfamily, Member 2,TNFalpha,Tumor Necrosis Factor,Cachectin Tumor Necrosis Factor,Tumor Necrosis Factor alpha

Related Publications

S Ohta, and M Harigai, and M Tanaka, and Y Kawaguchi, and T Sugiura, and K Takagi, and C Fukasawa, and M Hara, and N Kamatani
June 2004, The Journal of rheumatology,
S Ohta, and M Harigai, and M Tanaka, and Y Kawaguchi, and T Sugiura, and K Takagi, and C Fukasawa, and M Hara, and N Kamatani
January 2004, Przeglad lekarski,
S Ohta, and M Harigai, and M Tanaka, and Y Kawaguchi, and T Sugiura, and K Takagi, and C Fukasawa, and M Hara, and N Kamatani
August 1988, Journal of autoimmunity,
S Ohta, and M Harigai, and M Tanaka, and Y Kawaguchi, and T Sugiura, and K Takagi, and C Fukasawa, and M Hara, and N Kamatani
January 2002, The international journal of biochemistry & cell biology,
S Ohta, and M Harigai, and M Tanaka, and Y Kawaguchi, and T Sugiura, and K Takagi, and C Fukasawa, and M Hara, and N Kamatani
September 1991, Arthritis and rheumatism,
S Ohta, and M Harigai, and M Tanaka, and Y Kawaguchi, and T Sugiura, and K Takagi, and C Fukasawa, and M Hara, and N Kamatani
November 2000, Arthritis and rheumatism,
S Ohta, and M Harigai, and M Tanaka, and Y Kawaguchi, and T Sugiura, and K Takagi, and C Fukasawa, and M Hara, and N Kamatani
September 2001, The Journal of pharmacology and experimental therapeutics,
S Ohta, and M Harigai, and M Tanaka, and Y Kawaguchi, and T Sugiura, and K Takagi, and C Fukasawa, and M Hara, and N Kamatani
September 2006, The American journal of pathology,
S Ohta, and M Harigai, and M Tanaka, and Y Kawaguchi, and T Sugiura, and K Takagi, and C Fukasawa, and M Hara, and N Kamatani
August 1988, Arthritis and rheumatism,
S Ohta, and M Harigai, and M Tanaka, and Y Kawaguchi, and T Sugiura, and K Takagi, and C Fukasawa, and M Hara, and N Kamatani
January 2005, Nihon rinsho. Japanese journal of clinical medicine,
Copied contents to your clipboard!